Journal of Clinical Densitometry
Volume 13, Issue 4 , Pages 456-461 , October 2010

Prevalence of Bone Mineral Density Abnormalities and Related Risk Factors in an Ambulatory HIV Clinic Population

  • Silvia Guillemi

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
    • University of British Columbia, Vancouver, British Columbia, Canada
    • Corresponding Author InformationAddress correspondence to: Silvia Guillemi, MD, B526 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.
    • ,
  • Marianne Harris

      Affiliations

    • University of British Columbia, Vancouver, British Columbia, Canada
    • AIDS Research Program, Providence Health Care, Vancouver, British Columbia, Canada
    • ,
  • Gregory P. Bondy

      Affiliations

    • University of British Columbia, Vancouver, British Columbia, Canada
    • Lipid/Vascular Risk Reduction Clinic, Providence Health Care, Vancouver, British Columbia, Canada
    • ,
  • Francisco Ng

      Affiliations

    • AIDS Research Program, Providence Health Care, Vancouver, British Columbia, Canada
    • ,
  • Wendy Zhang

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
    • ,
  • Viviane D. Lima

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
    • ,
  • Clara E. Michaels

      Affiliations

    • AIDS Research Program, Providence Health Care, Vancouver, British Columbia, Canada
    • ,
  • Allan Belzberg

      Affiliations

    • Department of Nuclear Medicine, Providence Health Care, Vancouver, British Columbia, Canada
    • ,
  • Julio S. Montaner

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
    • University of British Columbia, Vancouver, British Columbia, Canada

Received 2 December 2009 ,Revised 28 May 2010 ,Accepted 1 June 2010.

References 

  1. Thomas J, Doherty SM. HIV infection, a risk factor for osteoporosis. J Acquir Immune Defic Syndr. 2003;33:281–291
  2. Brown T, Qaqish R. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165–2174
  3. Arnsten J, Freeman R, Howard A, et al. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007;21:617–623
  4. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93:3499–3504
  5. Bolland M, Grey A, Gamble G, Reid I. Low body weight mediates the relationship between HIV infections and low bone mineral density. A meta-analysis. J Clin Endocrinol Metab. 2007;92:4522–4528
  6. Jacobson D, Spiegelman D, Knox T, Wilson I. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr. 2008;49:298–308
  7. Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Groupe d'Epidemiologie Clinique du SIDA en Aguitaine Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 2008;22:395–402
  8. Mondy K, Yarasheski K, Powderly W, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36:482–490
  9. Mallon PWG. HIV and bone mineral density. Curr Opin Infect Dis. 2010;23:1–8
  10. Madeddu G, Spanu A, Solinas P, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004;48:39–48
  11. Brown T, McComsey G, King M, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51:554–561
  12. Duvivier C, Kolta S, Assoumou L, et al. the ANRS 121 Hippocampe Study Group Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naïve patients. AIDS. 2009;23:817–824
  13. Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 2009;23:1519–1529
  14. McComsey G, Kitch D, Darr E, et al. 2010 Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection. In: Program and Abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 16–19, 2010. Abstract 106LB.
  15. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients. A 3-year randomized trial. JAMA. 2004;292:191–201
  16. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009;49:1591–1601
  17. Castillo AB, Tarantal AF, Watnik MR, et al. Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone demineralization in growing rhesus monkeys (macaca mulatta). J Orthop Res. 2002;20:1185–1189
  18. Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of tenofovir to newborn and infant rhesus macaques. Antimicrob Agents Chemother. 2004;48:1469–1487
  19. The International Society for Clinical Densitometry (ISCD) Official Positions Statement. Available at http://www.iscd.org/Visitors/positions/OfficialPositionsText.cfmAccessed: March 23, 2010
  20. Hogg RS, Rhone SA, Yip B, et al. Antiviral effect of double and triple drug combinations among HIV- infected adults: lessons from the implementation of viral load-driven antiretroviral therapy. AIDS. 1998;12:279–284
  21. Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV infected individuals following initiation of triple and boosted combination antiretroviral regimens. AIDS. 2007;21:685–692
  22. Brown T, Ruppe M, Kassner R, et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab. 2004;89:1200–1206
  23. Calza L, Tapellini L, Farneti B, et al. Bone mass loss in patients with human immunodeficiency virus type 1 infection. Association with male sex and protease inhibitor therapy. Infect Dis Clin Pract. 2007;15:160–166
  24. van Vonderen MGA, Lips P, van Agtmael MA, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS. 2009;23:1367–1376
  25. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Miner Res. 1996;11:1531–1538
  26. Rosen C, Chestnut C, Mallinak N. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab. 1997;82:1904–1910
  27. Ravn P, Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab. 1999;84:2363–2368
  28. Chestnut C, Bell N, Clark G. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type 1 collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med. 1997;102:29–37

 This project was supported by a grant from GlaxoSmithKline Canada.

PII: S1094-6950(10)00197-6

doi: 10.1016/j.jocd.2010.06.001

Journal of Clinical Densitometry
Volume 13, Issue 4 , Pages 456-461 , October 2010

Article Tools